Medartis Holding AG (MDRSF) Stock Price & Analysis
Medartis Holding AG (MDRSF) — price $115.00 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.43B.
Educational signal · not a buy or sell recommendation · How to read this
Medartis Holding AG · MDRSF
Medartis Holding AG is a Switzerland-based medical technology firm specializing in advanced implant solutions for bone fracture repair in limbs and cranio-maxillofacial regions. Operating under APTUS and MODUS brands, the company globally develops, manufactures, and distributes specialized osteosynthesis instruments to healthcare providers.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $115.00 | |
| Change on the day | 0.00% | |
| Market capitalisation | $1.43B | |
| Price / earnings (trailing) | 93.00 | |
| Shares traded on the day | 217 |
Price & events
Other perspectives
Council score for Medartis Holding AG (MDRSF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 1, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 1, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Medartis Holding AG (MDRSF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Medartis Holding AG (MDRSF) is the company analyzed here. It employs 1,428 people. In Q2 FY2026 it reported revenue of CHF 160M and net income of CHF 5M. The market values it at $1.43B.
What do the latest results show for Medartis Holding AG (MDRSF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CHF 160M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CHF 160M | CHF 5M | CHF 0.41 (diluted) |
| Q4 FY2025 | CHF 146M | CHF 10M | CHF 0.79 (diluted) |
| Q2 FY2025 | CHF 123M | -CHF 1M | -CHF 0.12 (diluted) |
| Q4 FY2024 | CHF 113M | CHF 963,000 | CHF 0.07 (diluted) |
What are the financial strengths and risks for Medartis Holding AG (MDRSF)?
Short answer · as of
The distress and quality screens read Altman Z 3.02 · Piotroski F 6. Trailing ratios: ROE 5.4% · ROA 2.4% · current ratio 3.36 · earnings yield 1.1% · free-cash-flow yield 0.1%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MDRSF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MDRSF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About MDRSF
These answers are editorial: 1 of these 8 answers is drawn from the MDRSF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is MDRSF a good stock to buy?
Stock Expert AI does not rate MDRSF buy, sell or hold. Medartis Holding AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MDRSF stock price today?
The last price recorded for Medartis Holding AG (MDRSF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks associated with investing in MDRSF, particularly given its OTC listing?
Investing in Medartis Holding AG, especially as an OTC Other listed stock, involves several notable risks. A primary concern is the inherent liquidity risk associated with OTC Other securities, which typically exhibit lower trading volumes and wider bid-ask spreads compared to major exchange-listed stocks. This can make it challenging to execute trades efficiently.
What are the key factors to evaluate for MDRSF?
Evaluate MDRSF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. New Product Development and Innovation: Continuous investment in research and development to introduce new, more advanced, or minimally invasive implant solutions represents a key growth driver. Not financial advice.
How frequently does MDRSF data refresh on this page?
MDRSF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MDRSF's recent stock price performance?
Medartis Holding AG (MDRSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in high-precision surgical fixation implants for extremities and cranio-maxillofacial regions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MDRSF overvalued or undervalued right now?
The trailing P/E of Medartis Holding AG (MDRSF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MDRSF before investing?
Before investing in Medartis Holding AG (MDRSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 10 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com